Novartis Pharmaceuticals(NVS.US) successfully completed two Phase III studies of anti-BAFF-R monoclonal antibodies.

date
11/08/2025
According to the Securities Times app, on August 11th, Novartis Pharmaceuticals (NVS.US) announced that the two Phase III studies (NEPTUNUS-1 and NEPTUNUS-2) of Ianalumab (VAY736) for the treatment of active Sjgren's syndrome have achieved positive results. The drug is expected to become the first targeted therapy for Sjgren's syndrome.